Today via email:
We are pleased to advise that Delve Insight has published a report into the CAR T cell therapy market this week, in which Chimeric was noted as a "key company" within the space.
The report also highlights that the market is "is expected to grow significantly in the coming years, driven by the increasing incidence of cancer and the growing demand for personalized cancer treatments."
The full report can be accessed via the link below.
Regards
Jenn and Paul
Click here to view the report
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight (prnewswire.com)
GLTA
Chimeric: Media Thread, page-630
-
- There are more pages in this discussion • 261 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.002(20.0%) |
Mkt cap ! $11.70M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.3¢ | 1.0¢ | $153.9K | 13.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 128195 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 1224999 | 4 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |